SEARCH

SEARCH BY CITATION

References

  • 1
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998; 351: 1451-1467.
  • 2
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of randomised trials. Lancet. 2005; 365: 1687-1717.
  • 3
    Lim YC,Li L,Desta Z, et al. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther. 2004; 318: 503-512.
  • 4
    Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans, and their descendants. Pharmacogenomics. 2002; 3: 229-243.
  • 5
    Shimizu T,Ochiai H,Asell F, et al. Bioinformatics research on inter-racical difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharamacokinet. 2003; 18: 48-70.
  • 6
    Jin Y,Desta Z,Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005; 97: 30-39.
  • 7
    Goetz MP,Rae JM,Suman VJ, et al. Pharamacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005; 23: 9312-9318.
  • 8
    Myrand SP,Sekiguchi K,Man MZ, et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharamcol Ther. 2008; 84: 347-361.
  • 9
    Lim HS,Ju Lee H,Seok Lee K, et al. Clinical implications of CYP2D6 genotype predictive of tamoxifen pharamacokinetics in metastatic breast cancer. J Clin Oncol. 2007; 25: 3837-3845.
  • 10
    Kiyotani K,Mushiroda T,Sasa M, et al. Impact of CYP2D6 *10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 2008; 99: 995-999.
  • 11
    Xu Y,Sun Y,Yao L, et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol. 2008; 19: 1423-1429.
  • 12
    Schroth W,Antoniadou L,Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotype. J Clin Oncol. 2007; 25: 5187-5193.
  • 13
    Tassaneeyakul W,Mahatthanatrakul W,Niwatananun K, et al. CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab Pharmacokinet. 2006; 21: 286-290.
  • 14
    Strearns V,Johnson MD,Rae JM, et al. Active tamoxifen metabolite plasma concentration after coadministration of tamoxifen and selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003; 23: 1758-1764.
  • 15
    Goetz MP,Knox SK,Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007; 101: 113-121.
  • 16
    Parmar MK,Torri V,Stewart L, et al. Extracting summary statistics to perform meta-analyses of published literature for survival endpoints. Stat Med. 1998; 17: 2815-2834.
  • 17
    Wegman P,Elinqarami S,Carstensen J,Stal O,Nordenskjold B,Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer [serial online]. Breast Cancer Res. 2007; 9: R7.
  • 18
    Duffy S,Jackson TL,Lansdown M, et al. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Human Reprod. 2006; 21: 545-553.
  • 19
    Eastell R,Hannonn RA,Cuzick J,Dowsett M,Clack G,Adams JE;ATAC Trialists' Group. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res. 2006; 21: 1215-1223.
  • 20
    Boundred NJ. The effects of aromatase inhibitors on lipids and thrombosis. Br J Cancer. 2005; 93: S23-S27.
  • 21
    Baum M,Hackshaw A,Houghton J, et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from ZIPP study. Eur J Cancer. 2006; 42: 895-904.
  • 22
    Davidson NE,O'Neill AM,Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT0101(E5188). J Clin Oncol. 2005; 23: 5973-5982.